Bispecific PSMAxCD3 Antibody CC-1 in Patients With Squamous Cell Carcinoma of the Lung

NCT04496674 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped premature termination of the trial due to bad recruitment

Conditions

Lung Cancer Squamous Cell

Interventions

DRUG: CC-1 and Toczilizumab

Sponsor

German Cancer Research Center

Collaborators

[object Object]